Cervical Cancer Risk Factors for Biopsy: This Dataset is Obtained from UCI Repository and kindly acknowledged! This file contains a List of Risk Factors for Cervical Cancer leading to a Biopsy Examination! About 11,000 new cases of invasive cervical cancer are diagnosed each year in the U.S. However, the number of new cervical cancer cases has been declining steadily over the past decades. Although it is the most preventable type of cancer, each year cervical cancer kills about 4,000 women in the U.S. and about 300,000 women worldwide. In the United States, cervical cancer mortality rates plunged by 74% from 1955 - 1992 thanks to increased screening and early detection with the Pap test. AGE Fifty percent of cervical cancer diagnoses occur in women ages 35 - 54, and about 20% occur in women over 65 years of age. The median age of diagnosis is 48 years. About 15% of women develop cervical cancer between the ages of 20 - 30. Cervical cancer is extremely rare in women younger than age 20. However, many young women become infected with multiple types of human papilloma virus, which then can increase their risk of getting cervical cancer in the future. Young women with early abnormal changes who do not have regular examinations are at high risk for localized cancer by the time they are age 40, and for invasive cancer by age 50. SOCIOECONOMIC AND ETHNIC FACTORS Although the rate of cervical cancer has declined among both Caucasian and African-American women over the past decades, it remains much more prevalent in African-Americans -- whose death rates are twice as high as Caucasian women. Hispanic American women have more than twice the risk of invasive cervical cancer as Caucasian women, also due to a lower rate of screening. These differences, however, are almost certainly due to social and economic differences. Numerous studies report that high poverty levels are linked with low screening rates. In addition, lack of health insurance, limited transportation, and language difficulties hinder a poor woman’s access to screening services. HIGH SEXUAL ACTIVITY Human papilloma virus (HPV) is the main risk factor for cervical cancer. In adults, the most important risk factor for HPV is sexual activity with an infected person. Women most at risk for cervical cancer are those with a history of multiple sexual partners, sexual intercourse at age 17 years or younger, or both. A woman who has never been sexually active has a very low risk for developing cervical cancer. Sexual activity with multiple partners increases the likelihood of many other sexually transmitted infections (chlamydia, gonorrhea, syphilis).Studies have found an association between chlamydia and cervical cancer risk, including the possibility that chlamydia may prolong HPV infection. FAMILY HISTORY Women have a higher risk of cervical cancer if they have a first-degree relative (mother, sister) who has had cervical cancer. USE OF ORAL CONTRACEPTIVES Studies have reported a strong association between cervical cancer and long-term use of oral contraception (OC). Women who take birth control pills for more than 5 - 10 years appear to have a much higher risk HPV infection (up to four times higher) than those who do not use OCs. (Women taking OCs for fewer than 5 years do not have a significantly higher risk.) The reasons for this risk from OC use are not entirely clear. Women who use OCs may be less likely to use a diaphragm, condoms, or other methods that offer some protection against sexual transmitted diseases, including HPV. Some research also suggests that the hormones in OCs might help the virus enter the genetic material of cervical cells. HAVING MANY CHILDREN Studies indicate that having many children increases the risk for developing cervical cancer, particularly in women infected with HPV. SMOKING Smoking is associated with a higher risk for precancerous changes (dysplasia) in the cervix and for progression to invasive cervical cancer, especially for women infected with HPV. IMMUNOSUPPRESSION Women with weak immune systems, (such as those with HIV / AIDS), are more susceptible to acquiring HPV. Immunocompromised patients are also at higher risk for having cervical precancer develop rapidly into invasive cancer. DIETHYLSTILBESTROL (DES) From 1938 - 1971, diethylstilbestrol (DES), an estrogen-related drug, was widely prescribed to pregnant women to help prevent miscarriages. The daughters of these women face a higher risk for cervical cancer. DES is no longer prsecribed.

Users can access data about cancer statistics in the United States including but not limited to searches by type of cancer and race, sex, ethnicity, age at diagnosis, and age at death. Background Surveillance Epidemiology and End Results (SEER) database’s mission is to provide information on cancer statistics to help reduce the burden of disease in the U.S. population. The SEER database is a project to the National Cancer Institute. The SEER database collects information on incidence, prevalence, and survival from specific geographic areas representing 28 percent of the United States population. User functionality Users can access a variety of reso urces. Cancer Stat Fact Sheets allow users to look at summaries of statistics by major cancer type. Cancer Statistic Reviews are available from 1975-2008 in table format. Users are also able to build their own tables and graphs using Fast Stats. The Cancer Query system provides more flexibility and a larger set of cancer statistics than F ast Stats but requires more input from the user. State Cancer Profiles include dynamic maps and graphs enabling the investigation of cancer trends at the county, state, and national levels. SEER research data files and SEER*Stat software are available to download through your Internet connection (SEER*Stat’s client-server mode) or via discs shipped directly to you. A signed data agreement form is required to access the SEER data Data Notes Data is available in different formats depending on which type of data is accessed. Some data is available in table, PDF, and html formats. Detailed information about the data is available under “Data Documentation and Variable Recodes”.

This dataset contains Cancer Incidence data for Breast Cancer (Late Stage^) including: Age-Adjusted Rate, Confidence Interval, Average Annual Count, and Trend field information for US States for the average 5 year span from 2016 to 2020.Data are for females segmented by age (All Ages, Ages Under 50, Ages 50 & Over, Ages Under 65, and Ages 65 & Over), with field names and aliases describing the sex and age group tabulated.For more information, visit statecancerprofiles.cancer.govData NotationsState Cancer Registries may provide more current or more local data.TrendRising when 95% confidence interval of average annual percent change is above 0.Stable when 95% confidence interval of average annual percent change includes 0.Falling when 95% confidence interval of average annual percent change is below 0.† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.‡ Incidence Trend data come from different sources. Due to different years of data availability, most of the trends are AAPCs based on APCs but some are APCs calculated in SEER*Stat. Please refer to the source for each area for additional information.Rates and trends are computed using different standards for malignancy. For more information see malignant.^ Late Stage is defined as cases determined to be regional or distant. Due to changes in stage coding, Combined Summary Stage (2004+) is used for data from Surveillance, Epidemiology, and End Results (SEER) databases and Merged Summary Stage is used for data from National Program of Cancer Registries databases. Due to the increased complexity with staging, other staging variables maybe used if necessary.Data Source Field Key(1) Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.(5) Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.(6) Source: National Program of Cancer Registries SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention (based on the 2022 submission).(7) Source: SEER November 2022 submission.(8) Source: Incidence data provided by the SEER Program. AAPCs are calculated by the Joinpoint Regression Program and are based on APCs. Data are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84,85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used with SEER November 2022 data.Some data are not available, see Data Not Available for combinations of geography, cancer site, age, and race/ethnicity.Data for the United States does not include data from Nevada.Data for the United States does not include Puerto Rico.

SUMMARYThis analysis, designed and executed by Ribble Rivers Trust, identifies areas across England with the greatest levels of cancer (in persons of all ages). Please read the below information to gain a full understanding of what the data shows and how it should be interpreted.ANALYSIS METHODOLOGYThe analysis was carried out using Quality and Outcomes Framework (QOF) data, derived from NHS Digital, relating to cancer (in persons of all ages).This information was recorded at the GP practice level. However, GP catchment areas are not mutually exclusive: they overlap, with some areas covered by 30+ GP practices. Therefore, to increase the clarity and usability of the data, the GP-level statistics were converted into statistics based on Middle Layer Super Output Area (MSOA) census boundaries.The percentage of each MSOA’s population (all ages) with cancer was estimated. This was achieved by calculating a weighted average based on:The percentage of the MSOA area that was covered by each GP practice’s catchment areaOf the GPs that covered part of that MSOA: the percentage of registered patients that have that illness The estimated percentage of each MSOA’s population with cancer was then combined with Office for National Statistics Mid-Year Population Estimates (2019) data for MSOAs, to estimate the number of people in each MSOA with cancer, within the relevant age range.Each MSOA was assigned a relative score between 1 and 0 (1 = worst, 0 = best) based on:A) the PERCENTAGE of the population within that MSOA who are estimated to have cancerB) the NUMBER of people within that MSOA who are estimated to have cancerAn average of scores A & B was taken, and converted to a relative score between 1 and 0 (1= worst, 0 = best). The closer to 1 the score, the greater both the number and percentage of the population in the MSOA that are estimated to have cancer, compared to other MSOAs. In other words, those are areas where it’s estimated a large number of people suffer from cancer, and where those people make up a large percentage of the population, indicating there is a real issue with cancer within the population and the investment of resources to address that issue could have the greatest benefits.LIMITATIONS1. GP data for the financial year 1st April 2018 – 31st March 2019 was used in preference to data for the financial year 1st April 2019 – 31st March 2020, as the onset of the COVID19 pandemic during the latter year could have affected the reporting of medical statistics by GPs. However, for 53 GPs (out of 7670) that did not submit data in 2018/19, data from 2019/20 was used instead. Note also that some GPs (997 out of 7670) did not submit data in either year. This dataset should be viewed in conjunction with the ‘Health and wellbeing statistics (GP-level, England): Missing data and potential outliers’ dataset, to determine areas where data from 2019/20 was used, where one or more GPs did not submit data in either year, or where there were large discrepancies between the 2018/19 and 2019/20 data (differences in statistics that were > mean +/- 1 St.Dev.), which suggests erroneous data in one of those years (it was not feasible for this study to investigate this further), and thus where data should be interpreted with caution. Note also that there are some rural areas (with little or no population) that do not officially fall into any GP catchment area (although this will not affect the results of this analysis if there are no people living in those areas).2. Although all of the obesity/inactivity-related illnesses listed can be caused or exacerbated by inactivity and obesity, it was not possible to distinguish from the data the cause of the illnesses in patients: obesity and inactivity are highly unlikely to be the cause of all cases of each illness. By combining the data with data relating to levels of obesity and inactivity in adults and children (see the ‘Levels of obesity, inactivity and associated illnesses: Summary (England)’ dataset), we can identify where obesity/inactivity could be a contributing factor, and where interventions to reduce obesity and increase activity could be most beneficial for the health of the local population.3. It was not feasible to incorporate ultra-fine-scale geographic distribution of populations that are registered with each GP practice or who live within each MSOA. Populations might be concentrated in certain areas of a GP practice’s catchment area or MSOA and relatively sparse in other areas. Therefore, the dataset should be used to identify general areas where there are high levels of cancer, rather than interpreting the boundaries between areas as ‘hard’ boundaries that mark definite divisions between areas with differing levels of cancer.TO BE VIEWED IN COMBINATION WITH:This dataset should be viewed alongside the following datasets, which highlight areas of missing data and potential outliers in the data:Health and wellbeing statistics (GP-level, England): Missing data and potential outliersLevels of obesity, inactivity and associated illnesses (England): Missing dataDOWNLOADING THIS DATATo access this data on your desktop GIS, download the ‘Levels of obesity, inactivity and associated illnesses: Summary (England)’ dataset.DATA SOURCESThis dataset was produced using:Quality and Outcomes Framework data: Copyright © 2020, Health and Social Care Information Centre. The Health and Social Care Information Centre is a non-departmental body created by statute, also known as NHS Digital.GP Catchment Outlines. Copyright © 2020, Health and Social Care Information Centre. The Health and Social Care Information Centre is a non-departmental body created by statute, also known as NHS Digital. Data was cleaned by Ribble Rivers Trust before use.MSOA boundaries: © Office for National Statistics licensed under the Open Government Licence v3.0. Contains OS data © Crown copyright and database right 2021.Population data: Mid-2019 (June 30) Population Estimates for Middle Layer Super Output Areas in England and Wales. © Office for National Statistics licensed under the Open Government Licence v3.0. © Crown Copyright 2020.COPYRIGHT NOTICEThe reproduction of this data must be accompanied by the following statement:© Ribble Rivers Trust 2021. Analysis carried out using data that is: Copyright © 2020, Health and Social Care Information Centre. The Health and Social Care Information Centre is a non-departmental body created by statute, also known as NHS Digital; © Office for National Statistics licensed under the Open Government Licence v3.0. Contains OS data © Crown copyright and database right 2021. © Crown Copyright 2020.CaBA HEALTH & WELLBEING EVIDENCE BASEThis dataset forms part of the wider CaBA Health and Wellbeing Evidence Base.

Two datasets that explore causes of death due to cancer in South Africa, drawing on data from the Revised Burden of Disease estimates for the Comparative Risk Factor Assessment for South Africa, 2000. The number and percentage of deaths due to cancer by cause are ranked for persons, males and females in the tables below. Lung cancer is the leading cause of cancer in SA accounting for 17% of all cancer deaths. This is followed by oesophagus Ca which accounts for 13%, cervix cancer accounting for 8%, breast cancer accounting for 8% and liver cancer which accounts for 6% of all cancers. Many more males suffer from lung and oesophagus cancer than females.

Annual percent change and average annual percent change in age-standardized cancer incidence rates since 1984 to the most recent diagnosis year. The table includes a selection of commonly diagnosed invasive cancers, as well as in situ bladder cancer. Cases are defined using the Surveillance, Epidemiology and End Results (SEER) Groups for Primary Site based on the World Health Organization International Classification of Diseases for Oncology, Third Edition (ICD-O-3) from 1992 to the most recent data year and on the International Classification of Diseases, ninth revision (ICD-9) from 1984 to 1991.

Some racial and ethnic categories are suppressed for privacy and to avoid misleading estimates when the relative standard error exceeds 30% or the unweighted sample size is less than 50 respondents. Margins of error are estimated at the 90% confidence level.

Data Source: Centers for Disease Control and Prevention (CDC). Behavioral Risk Factor Surveillance System Survey (BRFSS) Data

Why This Matters

Colorectal cancer is the third leading cause of cancer death in the U.S. for men and women. Although colorectal cancer is most common among people aged 65 to 74, there has been an increase in incidences among people aged 40 to 49.

Nationally, Black people are disproportionately likely to both have colorectal cancer and die from it. Hispanic residents, and especially those with limited English proficiency, report having the lowest rate of colorectal cancer screenings.

Racial disparities in education, poverty, health insurance coverage, and English language proficiency are all factors that contribute to racial gaps in receiving colorectal cancer screenings. Increased colorectal cancer screening utilization has been shown to nearly erase the racial disparities in the death rate of colorectal cancer.

The District Response

The Colorectal Cancer Control Program (DC3C) aims to reduce colon cancer incidence and mortality by increasing colorectal cancer screening rates among District residents.

DC Health’s Cancer and Chronic Disease Prevention Bureau works with healthcare providers to improve the use of preventative health services and provide colorectal cancer screening services.

DC Health maintains the District of Columbia Cancer Registry (DCCR) to track cancer incidences, examine environmental substances that cause cancer, and identify differences in cancer incidences by age, gender, race, and geographical location.

This dataset contains Cancer Incidence data for Prostate Cancer(All Stages^) including: Age-Adjusted Rate, Confidence Interval, Average Annual Count, and Trend field information for US States for the average 5 year span from 2016 to 2020.Data are for males segmented age (All Ages, Ages Under 50, Ages 50 & Over, Ages Under 65, and Ages 65 & Over), with field names and aliases describing the sex and age group tabulated.For more information, visit statecancerprofiles.cancer.govData NotationsState Cancer Registries may provide more current or more local data.TrendRising when 95% confidence interval of average annual percent change is above 0.Stable when 95% confidence interval of average annual percent change includes 0.Falling when 95% confidence interval of average annual percent change is below 0.† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.‡ Incidence Trend data come from different sources. Due to different years of data availability, most of the trends are AAPCs based on APCs but some are APCs calculated in SEER*Stat. Please refer to the source for each area for additional information.Rates and trends are computed using different standards for malignancy. For more information see malignant.^ All Stages refers to any stage in the Surveillance, Epidemiology, and End Results (SEER) summary stage.Data Source Field Key(1) Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.(5) Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.(6) Source: National Program of Cancer Registries SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention (based on the 2022 submission).(7) Source: SEER November 2022 submission.(8) Source: Incidence data provided by the SEER Program. AAPCs are calculated by the Joinpoint Regression Program and are based on APCs. Data are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84,85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used with SEER November 2022 data.Some data are not available, see Data Not Available for combinations of geography, cancer site, age, and race/ethnicity.Data for the United States does not include data from Nevada.Data for the United States does not include Puerto Rico.

Some racial and ethnic categories are suppressed for privacy and to avoid misleading estimates when the relative standard error exceeds 30% or the unweighted sample size is less than 50 respondents.

Data Source: Centers for Disease Control and Prevention (CDC). Behavioral Risk Factor Surveillance System Survey (BRFSS) Data

Why This Matters

Breast cancer is the most commonly diagnosed cancer in women and people assigned female at birth (AFAB) and the second leading cause of cancer death in the U.S. Breast cancer screenings can save lives by helping to detect breast cancer in its early stages when treatment is more effective.

While non-Hispanic white women and AFAB individuals are more likely to be diagnosed with breast cancer than their counterparts of other races and ethnicities, non-Hispanic Black women and AFAB individuals die from breast cancer at a significantly higher rate than their counterparts races and ethnicities.

Later-stage diagnoses and prolonged treatment duration partly explain these disparities in mortality rate. Structural barriers to quality health care, insurance, education, affordable housing, and sustainable income that disproportionately affect communities of color also drive racial inequities in breast cancer screenings and mortality.

The District Response

Project Women Into Staying Healthy (WISH) provides free breast and cervical cancer screenings to uninsured or underinsured women and AFAB adults aged 21 to 64. Patient navigation, transportation assistance, and cancer education are also provided.

DC Health’s Cancer and Chronic Disease Prevention Bureau works with healthcare providers to improve the use of preventative health services and provide breast cancer screening services.

DC Health maintains the District of Columbia Cancer Registry (DCCR) to track cancer incidences, examine environmental substances that cause cancer, and identify differences in cancer incidences by age, gender, race, and geographical location.

Annual percent change and average annual percent change in age-standardized cancer mortality rates since 1984 to the most recent data year. The table includes a selection of commonly diagnosed invasive cancers and causes of death are defined based on the World Health Organization International Classification of Diseases, ninth revision (ICD-9) from 1984 to 1999 and on its tenth revision (ICD-10) from 2000 to the most recent year.

Proportion of patients examined within a standardized course of care out of the total number of people who are expected to receive a cancer diagnosis during the year. The calculation is based on data from the National Board of Health and Welfare. Standardized course of care (SVF) is a national approach that aims to reduce unnecessary waiting and uncertainty for the patient. All SVFs start with a well-founded suspicion of cancer. What is a well-founded suspicion, how it should be investigated and how long this may take, is stated in the national care program for each cancer diagnosis. The time from well-founded suspicion to the start of treatment is measured in the same way throughout the country. An SVF describes the investigations to be carried out in the event of suspicion of a particular cancer disease, as well as the maximum time limits within which the investigations must be completed and the first treatment must be started. The denominator consists of the total number of people who are expected to receive a cancer diagnosis during the year. The calculation is based on the number of cancer cases in the last three years with data from the Cancer Registry at the National Board of Health and Welfare.

Abstract Objective: To identify the socioepidemiologic and histopathologic patterns of lung cancer patients in the Middle Euphrates region. Patients and Methods: This study analyzed medical information from lung cancer patients at the Middle Euphrates Cancer Center in Iraq from January 2018 to December 2023. Demographic information (age, gender, residency, and education level) as well as clinical details (histopathological categorization) were obtained. The inclusion criteria included all confirmed lung cancer cases, while cases with inadequate data or non-lung cancer diagnosis were omitted. The data were analyzed using IBM SPSS Statistics (version 26). The data summarized using descriptive statistics, and chi-square tests used to identify correlations between categorical variables at a significance level of p < 0.05. Ethical approval was obtained from the relevant institutional review board. Results: A total of 1162 patients were included with mean age at diagnosis(64.47±11.45) years. Majority of patients are over 60 years (64.4%), followed by (40–60 years), 34%, and the least affected group is under 40 years (1.6%). Males account for the majority of cases (68%), while females about 32%, with male:female ratio that fluctuate around 2:1. Illiterate patients and those with low education levels represent the largest proportion accounting for about 87.9% of the study population. Squamous Cell Carcinoma (SCC) is the most frequent subtype (41.7%), followed closely by Adenocarcinoma (AC) at 37%, and Small Cell Lung Cancer (SCLC), 10.5%. Although SCC is the predominant subtype overall, AC incidence is increasing overtime (from 31.7% in 2018 to 41.4% in 2023) with predominance in females, younger and higher educated groups. While the percentage of SCLC and other less common subgroups remained relatively stable over time, there is a significant reduction in NSCLC-NOS diagnoses (from 11.1% in 2018 to 3.2% in 2023). Conclusions: In Iraq, specifically in the Middle Euphrates region, lung cancer is a major public health issue in the elder age groups. The two main subtypes, SCC and AC, are the main contributors, with obvious increment in AC cases in the recent years. The shifting trends indicate the urgent need for improved screening strategies, focused preventative initiatives, and customized treatment plans in view of changing risk profiles.

This dataset is sourced from Public Health England and consists of the percentage of people in the resident population eligible for cervical screening who were screened adequately within the previous years (2010 to 2016) for bowel, cervical and breast cancer.

This dataset contains Cancer Incidence data for Lung Cancer (All Stages^) including: Age-Adjusted Rate, Confidence Interval, Average Annual Count, and Trend field information for US States for the average 5 year span from 2016 to 2020.Data are segmented by sex (Both Sexes, Male, and Female) and age (All Ages, Ages Under 50, Ages 50 & Over, Ages Under 65, and Ages 65 & Over), with field names and aliases describing the sex and age group tabulated.For more information, visit statecancerprofiles.cancer.govData NotationsState Cancer Registries may provide more current or more local data.TrendRising when 95% confidence interval of average annual percent change is above 0.Stable when 95% confidence interval of average annual percent change includes 0.Falling when 95% confidence interval of average annual percent change is below 0.† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.‡ Incidence Trend data come from different sources. Due to different years of data availability, most of the trends are AAPCs based on APCs but some are APCs calculated in SEER*Stat. Please refer to the source for each area for additional information.Rates and trends are computed using different standards for malignancy. For more information see malignant.^ All Stages refers to any stage in the Surveillance, Epidemiology, and End Results (SEER) summary stage.Data Source Field Key(1) Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.(5) Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.(6) Source: National Program of Cancer Registries SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention (based on the 2022 submission).(7) Source: SEER November 2022 submission.(8) Source: Incidence data provided by the SEER Program. AAPCs are calculated by the Joinpoint Regression Program and are based on APCs. Data are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84,85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used with SEER November 2022 data.Some data are not available, see Data Not Available for combinations of geography, cancer site, age, and race/ethnicity.Data for the United States does not include data from Nevada.Data for the United States does not include Puerto Rico.

India IN: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data was reported at 19.800 NA in 2016. This records a decrease from the previous number of 20.000 NA for 2015. India IN: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data is updated yearly, averaging 21.200 NA from Dec 2000 (Median) to 2016, with 5 observations. The data reached an all-time high of 23.400 NA in 2000 and a record low of 19.800 NA in 2016. India IN: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s India – Table IN.World Bank.WDI: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted average;

Breast density is a radiologic feature that reflects fibroglandular tissue content relative to breast area or volume, and it is a breast cancer risk factor.

This study employed deep learning approaches to identify histologic correlates in radiologically-guided biopsies that may underlie breast density and distinguish cancer among women with elevated and low density.

Data access: Datasets supporting figure 2, tables 2 and 3 and supplementary table 2 of the published article are publicly available in the figshare repository, as part of this data record (https://doi.org/10.6084/m9.figshare.9786152). These datasets are contained in the zip file NPJ FigShare.zip. Datasets supporting figure 3, table 1 and supplementary table 1 of the published article are not publicly available to protect patient privacy, but can be made available on request from Dr. Gretchen L. Gierach, Senior Investigator, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA, email address: gierachg@mail.nih.gov.

Study description and aims: The study aimed to identify tissue correlates of breast density that may be important for distinguishing malignant from benign biopsy diagnoses separately among women with high and low breast density, to help inform cancer risk stratification among women undergoing a biopsy following an abnormal mammogram.

Haematoxylin and eosin (H&E)-stained digitized images from image-guided breast biopsies (n=852 patients) were evaluated. Breast density was assessed as global and localized fibroglandular volume (%). A convolutional neural network characterized H&E composition. 37 features were extracted from the network output, describing tissue quantities and morphological structure. A random forest regression model was trained to identify correlates most predictive of fibroglandular volume (n=588). Correlations between predicted and radiologically quantified fibroglandular volume were assessed in 264 independent patients. A second random forest classifier was trained to predict diagnosis (invasive vs. benign); performance was assessed using area under receiver-operating characteristics curves (AUC). For more details on the methodology please see the published article.

Study approval: The Institutional Review Boards at the NCI and the University of Vermont approved the protocol for this project for either active consenting or a waiver of consent to enrol participants, link data and perform analytical studies.

Dataset descriptions:

Data supporting figure 2: Datasets Figure 2A H&E.jpg, Figure 2A Mammogram.jpg, Figure 2B H&E.jpg and Figure 2B Mammogram.jpg are in .jpg file format and consist of histological whole slide H&E images and corresponding full-field digital mammograms from patients whose biopsies yielded diagnoses of atypical ductal hyperplasia and invasive carcinoma.

Data supporting figure 3: Dataset Figure 3.xls is in .xls file format and contains raw data used to generate the Receiver Operating Characteristic (ROC) curves for the prediction of invasive cancer among women with high percent global fibroglandular volume, low percent global fibroglandular volume, high percent localized fibroglandular volume and low percent localized fibroglandular volume.

Data supporting table 1: Dataset Table1_analysis.sas7bdat is in SAS file format and contains the characteristics of study participants in the BREAST Stamp Project, who were referred for an image-guided breast biopsy, stratified by the training and testing sets (n = 852).

Data supporting table 2: Datasets Global FGV.xls (accompanying Global FGV.png file) and Localized FGV.xls (accompanying Localized FGV.png file) are in .xls file format and the accompanying files are in .png file format. The data contain histologic features identified in the random forest model for the prediction of global and localized % fibroglandular volume.

Data supporting table 3: Datasets HighGlobal_feature_importance.xls, HighGlobal_feature_importance.pdf, HighLocal_feature_importance.xls, HighLocal_feature_importance.pdf, LowGlobal_feature_importance.xls, LowGlobal_feature_importance.pdf, LowLocal_feature_importance.xls, LowLocal_feature_importance.pdf are in .xls file format. The accompanying figures generated from the data in the .xls files are in .pdf file format. These files contain histologic features identified in the random forest model for the prediction of invasive cancer status among women with high vs. low % fibroglandular volume.

Data supporting supplementary table 1: Datasets testfeatures.xls and trainfeatures.xls are in .xls file format and include the distribution and description of the 37 histologic features extracted from the convolutional neural network deep learning output in the H&E stained whole slide images from the training and testing sets.

Data supporting supplementary table 2: Datasets All_samples_global.xls, All_samples_global.png, All_samples_local.xls, All_samples_local.png, PostMeno_global.xls, PostMeno_global.png, PostMeno_local.xls, PostMeno_local.png, PreMeno_global.xls, PreMeno_global.png, PreMeno_local.xls, PreMeno_local.png are in .xls file format. The accompanying figures generated from the data in the .xls files are in .png file format. These data include the histologic features identified in the random forest model that included BMI for the prediction of global and localized % fibroglandular volume.Software needed to access the data: Data files in SAS file format require the SAS software to be accessed.

Directly age-standardised registration rate for oral cancer (ICD-10 C00-C14), in persons of all ages, per 100,000 2013 European Standard PopulationRationaleTobacco is a known risk factor for oral cancers (1). In England, 65% of hospital admissions (2014–15) for oral cancer and 64 % of deaths (2014) due to oral cancer were attributed to smoking (2). Oral cancer registration is therefore a direct measure of smoking-related harm. Given the high proportion of these registrations that are due to smoking, a reduction in the prevalence of smoking would reduce the incidence of oral cancer.Towards a Smokefree Generation: A Tobacco Control Plan for England states that tobacco use remains one of our most significant public health challenges and that smoking is the single biggest cause of inequalities in death rates between the richest and poorest in our communities (3).In January 2012 the Public Health Outcomes Framework was published, then updated in 2016. Smoking and smoking related death plays a key role in two of the four domains: Health Improvement and Preventing premature mortality (4).References:(1) GBD 2013 Risk Factors Collaborators. Global, regional and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risk factors in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet 2015; 386:10010 2287–2323. (2) Statistics on smoking, England 2016, May 2016; http://content.digital.nhs.uk/catalogue/PUB20781 (3) Towards a Smokefree Generation: A Tobacco Control Plan for England, July 2017 https://www.gov.uk/government/publications/towards-a-smoke-free-generation-tobacco-control-plan-for-england (4) Public Health Outcomes Framework 2016 to 2019, August 2016; https://www.gov.uk/government/publications/public-health-outcomes-framework-2016-to-2019 Definition of numeratorCancer registrations for oral cancer (ICD-10, C00-C14) in the calendar years 2007-09 to 2017-2019. The National Cancer Registration and Analysis Service collects data relating to each new diagnosis of cancer that occurs in England. This does not include secondary cancers. Data are reported according to the calendar year in which the cancer was diagnosed.Definition of denominatorPopulation-years (ONS mid-year population estimates aggregated for the respective years) for people of all ages, aggregated into quinary age bands (0-4, 5-9,…, 85-89, 90+).CaveatsReviews of the quality of UK cancer registry data 1, 2 have concluded that registrations are largely complete, accurate and reliable. The data on cancer registration ‘quality indicators’ (mortality to incidence ratios, zero survival cases and unspecified site) demonstrate that although there is some variability, overall ascertainment and reliability is good. However cancer registrations are continuously being updated, so the number of registrations for each year may not be complete, as there is a small but steady stream of late registrations, some of which only come to light through death certification.1. Huggett C (1995). Review of the Quality and Comparability of Data held by Regional Cancer Registries. Bristol: Bristol Cancer Epidemiology Unit incorporating the South West Cancer Registry. 2. Seddon DJ, Williams EMI (1997). Data quality in population based cancer registration. British Journal of Cancer 76: 667-674.The data presented here replace versions previously published. Population data and the European Standard Population have been revised. ONS have provided an explanation of the change in standard population (available at http://www.ons.gov.uk/ons/guide-method/user-guidance/health-and-life-events/revised-european-standard-population-2013--2013-esp-/index.html )

This is a source dataset for a Let's Get Healthy California indicator at https://letsgethealthy.ca.gov/. Adult smoking prevalence in California, males and females aged 18+, starting in 2012. Caution must be used when comparing the percentages of smokers over time as the definition of ‘current smoker’ was broadened in 1996, and the survey methods were changed in 2012. Current cigarette smoking is defined as having smoked at least 100 cigarettes in lifetime and now smoking every day or some days. Due to the methodology change in 2012, the Centers for Disease Control and Prevention (CDC) recommend not conducting analyses where estimates from 1984 – 2011 are compared with analyses using the new methodology, beginning in 2012. This includes analyses examining trends and changes over time. (For more information, please see the narrative description.) The California Behavioral Risk Factor Surveillance System (BRFSS) is an on-going telephone survey of randomly selected adults, which collects information on a wide variety of health-related behaviors and preventive health practices related to the leading causes of death and disability such as cardiovascular disease, cancer, diabetes and injuries. Data are collected monthly from a random sample of the California population aged 18 years and older. The BRFSS is conducted by Public Health Survey Research Program of California State University, Sacramento under contract from CDPH. The survey has been conducted since 1984 by the California Department of Public Health in collaboration with the Centers for Disease Control and Prevention (CDC). In 2012, the survey methodology of the California BRFSS changed significantly so that the survey would be more representative of the general population. Several changes were implemented: 1) the survey became dual-frame, with both cell and landline random-digit dial components, 2) residents of college housing were eligible to complete the BRFSS, and 3) raking or iterative proportional fitting was used to calculate the survey weights. Due to these changes, estimates from 1984 – 2011 are not comparable to estimates from 2012 and beyond. Center for Disease Control and Policy (CDC) and recommend not conducting analyses where estimates from 1984 – 2011 are compared with analyses using the new methodology, beginning in 2012. This includes analyses examining trends and changes over time.Current cigarette smoking was defined as having smoked at least 100 cigarettes in lifetime and now smoking every day or some days. Prior to 1996, the definition of current cigarettes smoking was having smoked at least 100 cigarettes in lifetime and smoking now.

LT: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data was reported at 12.400 NA in 2016. This records a decrease from the previous number of 13.300 NA for 2015. LT: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data is updated yearly, averaging 14.100 NA from Dec 2000 (Median) to 2016, with 5 observations. The data reached an all-time high of 15.500 NA in 2005 and a record low of 12.400 NA in 2016. LT: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Lithuania – Table LT.World Bank.WDI: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted average;